Neurologia: eficácia das terapias de estimulação cerebral profunda no tratamento do Parkinson em pacientes com mais de 10 anos de diagnóstico
DOI:
https://doi.org/10.18378/rebes.v14i3.10791Abstract
This article addressed the efficacy of Deep Brain Stimulation (DBS) in the treatment of Parkinson's Disease in patients with more than ten years of diagnosis, a chronic neurodegenerative condition that impacts the quality of life of affected individuals. The problem investigated lies in the progression of motor and non-motor symptoms in the advanced stages of the disease, when conventional therapies, such as levodopa, become less effective and are associated with complications such as dyskinesias and motor fluctuations. In response to these challenges, the study aimed to evaluate the efficacy of DBS in improving symptoms and the quality of life of these patients, as well as to compare this therapeutic modality with other available interventions, including medication therapies and more recent techniques, such as levodopa-carbidopa intestinal gel infusion and high-intensity focused ultrasound. The methodology employed was a literature review, which included the analysis of clinical studies, systematic reviews, and meta-analyses available in the major scientific databases. The selection of articles was based on inclusion criteria that considered the relevance, currency, and methodological quality of the studies, focusing primarily on works that investigated the application of DBS in patients with more than ten years of Parkinson's Disease diagnosis. The results obtained indicated that DBS is an effective therapeutic modality in reducing motor symptoms and improving the quality of life of these patients, standing out compared to other therapeutic modalities analyzed. DBS allowed for a reduction in levodopa dosage, minimizing associated complications, and provided stabilization of symptoms throughout the day. It was also found that, despite the risks associated with the procedure, DBS presents an acceptable safety profile and benefits that outweigh the potential adverse effects, establishing itself as an important therapeutic option for patients with advanced Parkinson's Disease.
Downloads
References
BEUDEL, M.; BROWN, P. Adaptive deep brain stimulation in Parkinson's disease. Parkinsonism & related disorders, v. 22, p. S123-S126, 2016.
CABREIRA, V.; MASSANO, J. Doença de Parkinson: Revisão clínica e atualização. Acta Médica Portuguesa, v. 32, n. 10, p. 661-670, 2019.
CARBONI, E.; LINGOR, P. Insights on the interaction of alpha-synuclein and metals in the pathophysiology of Parkinson's disease. Metallomics, v. 7, n. 3, p. 395-404, 2015.
COLE, S. R. et al. Nonsinusoidal beta oscillations reflect cortical pathophysiology in Parkinson's disease. Journal of Neuroscience, v. 37, n. 18, p. 4830-4840, 2017.
DEMAAGD, G.; PHILIP, A. Parkinson’s disease and its management: part 1: disease entity, risk factors, pathophysiology, clinical presentation, and diagnosis. Pharmacy and therapeutics, v. 40, n. 8, p. 504, 2015.
DIRKX, M. F.; BOLOGNA, M. The pathophysiology of Parkinson's disease tremor. Journal of the Neurological Sciences, v. 435, p. 120196, 2022.
DORIA, M. et al. Contribution of cholesterol and oxysterols to the pathophysiology of Parkinson's disease. Free Radical Biology and Medicine, v. 101, p. 393-400, 2016.
DUBBIOSO, R. et al. Fast intracortical sensory-motor integration: a window into the pathophysiology of Parkinson’s disease. Frontiers in human neuroscience, v. 13, p. 111, 2019.
FANG, J. Y.; TOLLESON, C. The role of deep brain stimulation in Parkinson’s disease: an overview and update on new developments. Neuropsychiatric disease and treatment, p. 723-732, 2017.
HABETS, J. G. V et al. An update on adaptive deep brain stimulation in Parkinson's disease. Movement Disorders, v. 33, n. 12, p. 1834-1843, 2018.
HARTMANN, C. J. et al. An update on best practice of deep brain stimulation in Parkinson’s disease. Therapeutic Advances in Neurological Disorders, v. 12, p. 1756286419838096, 2019.
HICKEY, P.; STACY, M. Deep brain stimulation: a paradigm shifting approach to treat Parkinson's disease. Frontiers in neuroscience, v. 10, p. 173, 2016.
KURTIS, M. M. et al. The effect of deep brain stimulation on the non-motor symptoms of Parkinson’s disease: a critical review of the current evidence. npj Parkinson's Disease, v. 3, n. 1, p. 1-12, 2017.
LEE, P. S.; CRAMMOND, D. J.; RICHARDSON, R. M. Deep brain stimulation of the subthalamic nucleus and globus pallidus for Parkinson's disease. Current Concepts in Movement Disorder Management, v. 33, p. 207-221, 2018.
LEWITT, P. A. Levodopa therapy for Parkinson's disease: pharmacokinetics and pharmacodynamics. Movement Disorders, v. 30, n. 1, p. 64-72, 2015.
LIMOUSIN, P.; FOLTYNIE, T. Long-term outcomes of deep brain stimulation in Parkinson disease. Nature Reviews Neurology, v. 15, n. 4, p. 234-242, 2019.
LITTLE, S. et al. Bilateral adaptive deep brain stimulation is effective in Parkinson's disease. Journal of Neurology, Neurosurgery & Psychiatry, v. 87, n. 7, p. 717-721, 2016.
LITTLE, S.; BROWN, P. Debugging adaptive deep brain stimulation for Parkinson's disease. Movement Disorders, v. 35, n. 4, p. 555-561, 2020.
MAGRINELLI, F. et al. Pathophysiology of motor dysfunction in Parkinson’s disease as the rationale for drug treatment and rehabilitation. Parkinson’s disease, v. 2016, n. 1, p. 9832839, 2016.
MALEK, N. Deep brain stimulation in Parkinson's disease. Neurology India, v. 67, n. 4, p. 968-978, 2019.
MARIE, A. et al. Role and mechanism of vitamin A metabolism in the pathophysiology of Parkinson’s disease. Journal of Parkinson's disease, v. 11, n. 3, p. 949-970, 2021.
MARINO, B. L. B et al. Parkinson’s disease: a review from pathophysiology to treatment. Mini reviews in medicinal chemistry, v. 20, n. 9, p. 754-767, 2020.
MARTINEZ, D. et al. Update on deep brain stimulation in Parkinson’s disease. Translational Neurodegeneration, v. 4, p. 1-8, 2015.
MOOSA, S. et al. The role of high‐intensity focused ultrasound as a symptomatic treatment for Parkinson's disease. Movement Disorders, v. 34, n. 9, p. 1243-1251, 2019.
MULEIRO, M. et al. A comprehensive approach to Parkinson’s disease: addressing its molecular, clinical, and therapeutic aspects. International Journal of Molecular Sciences, v. 25, n. 13, p. 7183, 2024.
NAIR, A. T. et al. Gut microbiota dysfunction as reliable non-invasive early diagnostic biomarkers in the pathophysiology of Parkinson’s disease: a critical review. Journal of Neurogastroenterology and Motility, v. 24, n. 1, p. 30, 2018.
NEMADE, D.; SUBRAMANIAN, T.; SHIVKUMAR, V. An update on medical and surgical treatments of Parkinson’s disease. Aging and disease, v. 12, n. 4, p. 1021, 2021.
PAFF, M. et al. Update on current technologies for deep brain stimulation in Parkinson’s disease. Journal of movement disorders, v. 13, n. 3, p. 185, 2020.
REZAEI, O. et al. Assessment of the role of non-coding RNAs in the pathophysiology of Parkinson's disease. European Journal of Pharmacology, v. 896, p. 173914, 2021.
RIEDERER, P; MÜLLER, T. Monoamine oxidase-B inhibitors in the treatment of Parkinson’s disease: Clinical–pharmacological aspects. Journal of Neural Transmission, v. 125, n. 11, p. 1751-1757, 2018.
SAENGER, V. M. et al. Uncovering the underlying mechanisms and whole-brain dynamics of deep brain stimulation for Parkinson’s disease. Scientific reports, v. 7, n. 1, p. 9882, 2017.
SCHULZ, W. J. Is cell death primary or secondary in the pathophysiology of idiopathic Parkinson’s disease?. Biomolecules, v. 5, n. 3, p. 1467-1479, 2015.
SIMON, D. K.; TANNER, Caroline M.; BRUNDIN, Patrik. Parkinson disease epidemiology, pathology, genetics, and pathophysiology. Clinics in geriatric medicine, v. 36, n. 1, p. 1-12, 2020.
TINKHAUSER, G. et al. The modulatory effect of adaptive deep brain stimulation on beta bursts in Parkinson’s disease. Brain, v. 140, n. 4, p. 1053-1067, 2017.
VARMES, P. H. D. et al. Análise da eficácia da estimulação cerebral profunda na doença de Parkinson. Revista Eletrônica Acervo Médico, v. 24, p. e14743-e14743, 2024.
VÁZQUEZ, G. E.; ZOGHBI, H. Y. Parkinson's disease genetics and pathophysiology. Annual review of neuroscience, v. 44, n. 1, p. 87-108, 2021.
WIRDEFELDT, K; ODIN, P; NYHOLM, D. Levodopa–carbidopa intestinal gel in patients with Parkinson’s disease: a systematic review. CNS drugs, v. 30, p. 381-404, 2016.
ZAMAN, V. et al. Cellular and molecular pathophysiology in the progression of Parkinson’s disease. Metabolic brain disease, v. 36, p. 815-827, 2021.
Downloads
Published
Versions
- 2024-08-10 (2)
- 2024-08-10 (1)
How to Cite
Issue
Section
License
Copyright (c) 2024 Felipe Maia da Fonsêca , Lucas Patrick Silva Batista, Miguel Lopes Gomes , Clara de Araújo Dantas Teixeira , Giselle Cândida Pires Silva , Maria isabel Teles Nogueira , Eluany Nogueira de Freitas , Marina Oliveira Ferreira
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Termo de cess